Douglas Swirsky Elected to the Board of Directors of PolyMedix

RADNOR, Pa.--(Business Wire)--
PolyMedix, Inc. (OTC BB: PYMX, www.polymedix.com), an emerging biotechnology
company developing acute care products for infectious diseases and acute
cardiovascular disorders,held its annual meeting of stockholders on June 30,
2009 at which Douglas Swirsky was newly elected to serve on the Board of
Directors. At the annual meeting, stockholders also re-elected seven incumbent
directors to continue to serve on the Board.

Douglas J. Swirsky presently serves as Senior Vice President, Chief Financial
Officer, Treasurer, and Corporate Secretary of GenVec, Inc., a biopharmaceutical
company, a position he has held since 2006. Prior to joining GenVec, Mr. Swirsky
was a Managing Director and the Head of Life Sciences Investment Banking at
Stifel Nicolaus and held the same position at Legg Mason prior to Stifel
Financial`s acquisition of the Legg Mason Capital Markets business in 2005. Mr.
Swirsky, a Certified Public Accountant and a CFA charterholder, has also
previously held investment banking positions at UBS, PaineWebber, and Morgan
Stanley. His experience also includes positions in public accounting and
consulting. Mr. Swirsky received his B.S. in Business in Administration from
Boston University and his M.B.A. from the Kellogg School of Management at
Northwestern University.

"We welcome Doug to the Board of PolyMedix. His experiences in life sciences
banking and finance compliment and bring valuable additional skills and
expertise to our Board. We look forward to working with Doug as we continue to
build PolyMedix," commented Nicholas Landekic, President & C.E.O. of PolyMedix.

About PolyMedix, Inc.

PolyMedix is a publicly traded emerging biotechnology company focused on the
development of novel drugs and biomaterials for the treatment of infectious
diseases and acute cardiovascular disorders. PolyMedix`s compounds are based on
biomimetics: non-peptide small molecule drug candidates that mimic the activity
of proteins. The Company`s antibiotic compounds, including PMX-30063 - small
molecule mimetics of human host-defense proteins - have a mechanism of action
distinct from those of current antibiotic drugs, a mechanism which is intended
to make bacterial resistance unlikely to develop. The Company`s goal is to
develop these as rapidly acting antibiotics for serious systemic and local
infections. The Company plans to continue the development of polymeric
formulations as antimicrobial biomaterials, which can be used as additives to
paints, plastics, and textiles to create self-sterilizing products and surfaces.
The Company`s heptagonist compounds, including PMX-60056, reverse the activity
of both heparin and Low Molecular Weight Heparins, with the goal of developing
an antagonist drug that is safer and easier to use than currently approved
therapy. For more information, please visit PolyMedix on its website at
www.polymedix.com.

This press release contains forward-looking statements made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act of 1995 that
involve risks, uncertainties and assumptions that could cause PolyMedix`s actual
results and experience to differ materially from anticipated results and
expectations expressed in these forward looking statements. PolyMedix has in
some cases identified forward-looking statements by using words such as
"anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans,"
"intends", "goal", "potential," "may," "suggest," and similar expressions. Among
other factors that could cause actual results to differ materially from those
expressed in forward-looking statements, PolyMedix`s compounds may not enter or
successfully complete clinical testing or be granted regulatory approval to be
sold and marketed in the United States or elsewhere. A more complete description
of these factors is included in PolyMedix`s filings with the Securities and
Exchange Commission. You should not place undue reliance on any forward-looking
statements. PolyMedix undertakes no obligation to release publicly the results
of any revisions to any such forward-looking statements that may be made to
reflect events or circumstances after the date of this press release or to
reflect the occurrence of unanticipated events, except as required by applicable
law or regulation.

PolyMedix, Inc.
Lona Cornish, 484-598-2340
lcornish@polymedix.com
or
The Investor Relations Group
212-825-3210
Investors: Erika Moran
emoran@investorrelationsgroup.com
Media: Janet Vasquez
jvasquez@investorrelationsgroup.com

Copyright Business Wire 2009